All In Biotech

Drug Trial Radar · NCT07619118

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

A Phase III Randomised, Double-Blind, Parallel-Group Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared With Rosuvastatin on Low-Density Lipoprotein Cholesterol in Patients With Hypercholesterolaemia

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Sep 10, 2026

Primary completion

May 28, 2027

Study completion May 28, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect on low-density lipoprotein-cholesterol (LDL-C) and the safety and tolerability of a fixed dose combination (FDC) of laroprovstat/rosuvastatin versus rosuvastatin alone in patients with hypercholesterolaemia with either a history of a clinical atherosclerotic cardiovascular disease (ASCVD) event or at increased risk for a first clinical ASCVD event.

Conditions

  • Hypercholesterolaemia

Interventions

  • laroprovstat/rosuvastatin 1Combination product

    daily oral dose of the laroprovstat/rosuvastatin 1

  • laroprovstat/rosuvastatin 2Combination product

    daily oral dose of the laroprovstat/rosuvastatin 2

  • laroprovstat/rosuvastatin 3Combination product

    daily oral dose of the laroprovstat/rosuvastatin 3

  • laroprovstat/rosuvastatin 4Combination product

    daily oral dose of the laroprovstat/rosuvastatin 4

  • Placebo to match laroprovstat/rosuvastatin 1,2,3Drug

    Daily oral dose of placebo to match FDC laroprovstat/rosuvastatin 1,2,3

  • Placebo to match laroprovstat/rosuvastatin 4Drug

    Daily oral dose of placebo to match FDC laroprovstat/rosuvastatin 4

  • Rosuvastatin 1Drug

    daily oral dose of rosuvastatin 1

  • Rosuvastatin 2Drug

    daily oral dose of rosuvastatin 2

  • Rosuvastatin 3Drug

    daily oral dose of rosuvastatin 3

  • Rosuvastatin 4Drug

    daily oral dose of rosuvastatin 4

  • Placebo to match RosuvastatinDrug

    daily oral dose of placebo to match rosuvastatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in LDL-C at 8 weeksTime frame: 8 weeks

Locations

45 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Sun City West, Arizona · Recruiting

  • Research Site

    Gardena, California · Not yet recruiting

  • Research Site

    Lomita, California · Not yet recruiting

  • Research Site

    Pomona, California · Recruiting

  • Research Site

    Sacramento, California · Not yet recruiting

  • Research Site

    Jacksonville, Florida · Not yet recruiting

  • Research Site

    Miami Lakes, Florida · Recruiting

  • Research Site

    Orlando, Florida · Not yet recruiting

  • Research Site

    Pembroke Pines, Florida · Not yet recruiting

  • Research Site

    Conyers, Georgia · Recruiting

  • Research Site

    Decatur, Georgia · Recruiting

  • Research Site

    Peachtree Corners, Georgia · Not yet recruiting

  • Research Site

    Evansville, Indiana · Not yet recruiting

  • Research Site

    Indianapolis, Indiana · Withdrawn

  • Research Site

    Zachary, Louisiana · Not yet recruiting

  • Research Site

    Beltsville, Maryland · Recruiting

  • Research Site

    Rocky Mount, North Carolina · Not yet recruiting

  • Research Site

    Statesville, North Carolina · Not yet recruiting

  • Research Site

    Wilmington, North Carolina · Not yet recruiting

  • Research Site

    Fargo, North Dakota · Not yet recruiting

  • Research Site

    Anderson, South Carolina · Not yet recruiting

  • Research Site

    Bristol, Tennessee · Not yet recruiting

  • Research Site

    Houston, Texas · Not yet recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Mesquite, Texas · Recruiting

  • Research Site

    Sugar Land, Texas · Recruiting

  • Research Site

    Burwood, Australia · Not yet recruiting

  • Research Site

    Hope Island, Australia · Recruiting

  • Research Site

    Hoppers Crossing, Australia · Not yet recruiting

  • Research Site

    Woolloongabba, Australia · Recruiting

  • Research Site

    Cambridge, Ontario, Canada · Suspended

  • Research Site

    Guelph, Ontario, Canada · Recruiting

  • Research Site

    Mississauga, Ontario, Canada · Recruiting

  • Research Site

    North York, Ontario, Canada · Recruiting

  • Research Site

    Stoney Creek, Ontario, Canada · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Recruiting

  • Research Site

    Berlin, Germany · Not yet recruiting

  • Research Site

    Essen, Germany · Not yet recruiting

  • Research Site

    Frankfurt, Germany · Not yet recruiting

  • Research Site

    Freiburg im Breisgau, Germany · Not yet recruiting

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.